UK markets closed

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
48.96-0.87 (-1.75%)
At close: 04:00PM EDT
48.96 0.00 (0.00%)
After hours: 07:50PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • A
    Anna
    To be a super-trader, you'll need an edge to overcome the laws of probability and the uncertainty of the marketplace. That edge comes from information flow, the ability to correct your habits in terms of the markets characteristics, and being able to learn from people who knows more than you, cut losses, expand your information network, ferret out ideas, and take recommendations.
  • J
    Janet
    Exas moonshot MCED study announcement shows that Exas is way ahead of GH.
  • s
    sornson
    I am so tired of GH doing nothing all day. Can you move??? I have been reading www.daytradercompany.tech for a month now and the stocks there actually go!
  • L
    Lipstick on a pig
    Exact Sciences Corporation
    got $GH? ... market leader in liquid biopsy for the foreseeable future (5+ years)
  • A
    ARC
    Credit Sussie initiated coverage of Guardant Health at outperform with a $80 price target
  • F
    Frank
    Up ward trend
  • A
    ARC
    PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant Reveal™ molecular residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after surgery to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy. It is the first blood-only liquid biopsy test available for MRD testing in patients with colorectal cancer (CRC).
  • B
    Benjo
    I see big resistance at $71. I have no position, but power play charts says $71 !
  • A
    ARC
    Positive report from MorningStar
  • S
    Steven
    Just reading thru the GH ER presentation. They presented some data regarding adoption levels at different efficacy levels in (get this!) 2032. Ten years from now?!? Okkkkkk. That’s what I call a long term investment! Go EXAS! $GH
  • L
    Lipstick on a pig
    Exact Sciences Corporation
    Medicare approval for Guardant Reveal ... $GH extends their dominance in liquid biopsy
  • F
    Frank
    Hope GH has a positive Earnings in the coming ER
  • x
    xav
    Expectations for the 2nd quarter report?
  • J
    Jim
    Oops, off almost 12% last week. The chart for the week looks like a set of stairs headed to the cellar, or should that be Seller?
  • J
    Jim
    Well, $57.29 looked s lot better earlier this month. Time for another forecast reduction to about $75??
  • J
    Joe
    ARKG buying again.
  • A
    ARC
    PALO ALTO, Calif., August 31, 2022--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, to further leverage the GuardantINFORM real-world evidence (RWE) platform to help accelerate development efforts for Merck KGaA, Darmstadt, Germany‘s precision oncology pipeline. The expanded strategic collaboration will focus on therapy development for core cancer indications with significant unmet need.
  • n
    neil
    Could use some PR news from management.
  • J
    Jim
    Nice closing hour. Must be getting rid of those shares before the bad news in delivered this afternoon.
  • J
    Jim
    Guardant Health (GH) came out with a quarterly loss of $2.25 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss of $0.96 per share a year ago. These figures are adjusted for non-recurring items

    The only surprise here should be the poor estimate by the Zack’s Wall St. analists. If they could just see siht as it really is, then no one holding would be a loser.